Insulin glulisine: all 65 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's DiseaseTerminatedNCT02503501Phase 2Results posted
• Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DMCompletedNCT01855243Not applicableResults posted
• Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) PatientsCompletedNCT01792830Phase 3Results posted
• Effect of Apidra Compared to Humalog in Decreasing Post-Prandial HyperglycemiaCompletedNCT01621776Not applicableResults posted
• Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.CompletedNCT01436045Phase 2Results posted
• Diabetes in the Elderly: Prospective StudyCompletedNCT01131052Phase 4Results posted
• The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal ChildrenCompletedNCT00913497Phase 4Results posted
• Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial InfarctionTerminatedNCT00670228Phase 3Results posted
• Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes MellitusCompletedNCT00607087Phase 4Results posted
• Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General SurgeryCompletedNCT00596687Phase 4Results posted
• Insulin Glargine "All to Target" TrialCompletedNCT00384085Phase 4Results posted
• Insulin Glulisine in Type 2 Diabetic PatientsCompletedNCT00360698Phase 4Results posted
• Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus PatientsCompletedNCT07070752Phase 3
• The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.CompletedNCT04124302Phase 4
• Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index MealCompletedNCT04019821Phase 4
• Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyCompletedNCT03359837Phase 4
• Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)CompletedNCT03328845Phase 4
• Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)CompletedNCT02914886Phase 4
• A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusCompletedNCT02910518Phase 1
• Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.Status unknownNCT02685449Phase 4
• Normal Versus Dual Wave Insulin Bolus for High-protein FoodCompletedNCT02276859Phase 4
• Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 DiabetesTerminatedNCT02048189Phase 4
• Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes MellitusCompletedNCT01678235Phase 4
• Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational DiabetesCompletedNCT01662921Phase 2
• Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical WardsCompletedNCT01594060Phase 4
• Establishing Cardiovascular Biomarkers to Define Preferred Lantus® UseStatus unknownNCT01500850Phase 4
• Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot StudyStatus unknownNCT01417897Phase 4
• Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a DayCompletedNCT01234597Phase 4
• Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)CompletedNCT01212913Phase 4
• baSal BoluS Therapy in patIenTs With TypE 1 Diabetes MellitusCompletedNCT01204593Phase 4
• Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering DrugsCompletedNCT01203111Phase 4
• Apidra Children & Adolescents StudyCompletedNCT01202474Phase 4
• Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin AspartCompletedNCT01159353Phase 1
• Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use SettingTerminatedNCT01079364Phase 4
• Self Titration With Apidra to Reach Target Study (START)CompletedNCT01013571Phase 4
• Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy VolunteersCompletedNCT00969592Phase 1
• Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsCompletedNCT00965549Phase 4
• Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes MellitusCompletedNCT00964574Phase 4
• Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult ControlsCompletedNCT00927524Not applicable
• Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 DiabetesCompletedNCT00824668Phase 1
• Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 DiabetesCompletedNCT00562133Phase 3
• Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics StudyCompletedNCT00539448Phase 4
• Comparison of Apidra to Regular Insulin in Hospitalized PatientsCompletedNCT00528918Not applicable
• Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes MellitusCompletedNCT00526513Phase 4
• APIDRA Registration StudyCompletedNCT00489190Phase 4
• Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) ExacerbationsTerminatedNCT00467636Not applicable
• Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes MellitusCompletedNCT00467376Phase 3
• Insulin Glulisine, Diabetes Mellitus Type 1CompletedNCT00397553Phase 3
• Dose-Exposure-Response in Type 1 Diabetes MellitusCompletedNCT00368394Phase 1
• Insulin Glulisine in Healthy Lean and Obese SubjectsCompletedNCT00311077Phase 1
• Insulin Glulisine in Type 2 Diabetes MellitusCompletedNCT00310297Phase 1
• Insulin Glulisine in Type 1 Diabetes MellitusCompletedNCT00297583Phase 1
• Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes MellitusCompletedNCT00290979Phase 3
• Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes MellitusCompletedNCT00290927Phase 3
• Glulisine Pre- and PostmealCompletedNCT00290043Phase 1
• ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.CompletedNCT00272064Phase 3
• OPAL - Insulin Glulisine, Diabetes MellitusCompletedNCT00272012Phase 3
• Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic PatientsCompletedNCT00271284Phase 3
• Insulin Glulisine in Diabetes Mellitus, Type 2CompletedNCT00174668Phase 3
• Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)CompletedNCT00135941Phase 3
• Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal InsulinCompletedNCT00135096Phase 3
• Variable Bolus Regimen 1-2-3 for Type 2 Diabetes MellitusCompletedNCT00135083Phase 3
• Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal InsulinCompletedNCT00135057Phase 3
• Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and AdolescentsCompletedNCT00115570Phase 3
• 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.CompletedNCT00046150Phase 3

← Insulin glulisine overview